Viral cold diseases J06.9
Conditions
Interventions
Group 1: Patients with acute cold symptoms who opted for treatment with Esberitox® COMPACT will record their disease progression over maximum 10 treatment days in a cold diary. The package leaflet of
Sponsors
Schaper & Brümmer GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients who intend to treat their acute cold with Esberitox® COMPACT in line with the package information leaflet and who are invited by the pharmacist / the qualified staff to participate in the study. - Written data collection consent has been obtained.
Exclusion criteria
Exclusion criteria: Contraindications of Esberitox® COMPACT according to the package information leaflet.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the risk-benefit ratio of Esberitox® COMPACT under everyday conditions by using a cold diary and by - collection of essential cold symptoms (global cold; rhinitis score; bronchitis score; general complaints; total score) at treatment start and every 1 – 2 days during the maximum 10-day treatment and of the overall assessment of efficacy after the last application by the patient ('benefit') - collection of adverse drug reactions during the course of treatment and of the overall assessment of tolerability after the last application by the patient ('risk'). | — |
Secondary
| Measure | Time frame |
|---|---|
| Collection of the overall assessment of patient satisfaction with the treatment after the last application by using a cold diary. | — |
Countries
Germany
Contacts
Public ContactJörg Schnitker
Institut für angewandte Statistik Dr. Jörg Schnitker GmbH (IAS)
Outcome results
None listed